M. Tomirotti - Concepedia

Author

M. Tomirotti

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Also Known As

M TOMIROTTI, M Tomirotti, M. Tomirotti, Martina Tomirotti, Maurizio Tomirotti, WW ten Bokkel Huinink

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Azienda Ospedaliera Fatebenefratelli e Oftalmico Azienda Ospedaliera San Giovanni Addolorata Mario Negri Institute for Pharmacological Research Ospedale di Belcolle

About

M. Tomirotti is an author at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	726
2	Health Sciences	5	5	139
3	Gastroenterology	2	2	59
4	Public Health	1	1	39
5	Allergy	1	1	10

M. Tomirotti

Publications

995

Citations

H-Index

Page 1

	Year	Citations
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Marina Chiara Garassino, Olga Martelli, Massimo Broggini, The Lancet Oncology Second-line TreatmentOncologyWild-type Egfr TumoursMetronomic TherapyPathology	2013	476
Complications of Subcutaneous Infusion Port in the General Oncology Population C Ballarini, Mattia Intra, Andrea Pisani Ceretti, Oncology	1999	129
Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients Andrés J.M. Ferreri, Michele Reni, Stefania Dell’Oro, Oncology	2001	94
TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR. Marina Chiara Garassino, Olga Martelli, Anna Bettini, Journal of Clinical Oncology Surgical OncologyCancer ManagementPathologyPharmacotherapySecond-line Treatment	2012	54
Serum Copper and Ceruloplasmin Levels in Patients with Neoplasias Localized in the Stomach, Large Intestine or Lung A. Scanni, Luciano Licciardello, Marinella Trovato, Tumori Journal Serum CopperGastrointestinal OncologyMedicineHistopathologyGastroenterology	1977	43
Ischemic Cardiopathy from CIS-Diamminedichloroplatinum (CDDP) M. Tomirotti, Romeo Riundi, Sergio Pillici, Tumori Journal ThrombosisCardiomyopathyHeart FailureOncologyCardiovascular Disease	1984	39
TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. Marina Chiara Garassino, Olga Martelli, Anna Bettini, Journal of Clinical Oncology PathologyPharmacotherapySecond-line TreatmentOncologyDocetaxel 110	2012	28
Paclitaxel-Dependent Prolonged and Persistent Complete Remission Four Years from First Recurrence of Secondary Breast Angiosarcoma Donatella Gambini, Roberto Visintin, Elisa Locatelli, Tumori Journal Surgical OncologyBreast OncologyPathologyWeekly PaclitaxelRadiation-induced Breast Sarcomas	2009	25
Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma. Donatella Gambini, Roberto Visintin, Elisa Locatelli, PubMed	2010	19
RECOVERY OF RESPONSE TO ADRIAMYCIN AND CYCLOPHOSPHAMIDE BY LONIDAMINE IN PREVIOUSLY TREATED METASTATIC BREAST-CANCER PATIENTS M. Tomirotti, Grisi Bernardo, C. Epifani, International Journal of Oncology Phase 11Metastatic Breast CancerOncologyBreast OncologyOral Lonidamine	1993	19

Page 1